Skip to content

Study on the difference of cerebrospinal fluid proteomics and metabolomics between young and old people with sleep disorders

Study on the difference of cerebrospinal fluid proteomics and metabolomics between young and old people with sleep disorders

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064072
Enrollment
Unknown
Registered
2022-09-25
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aging

Interventions

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Sign written informed consent are from the subjects prior to any examination, sampling or analysis the data 2. aged 18-20 years and 75-85 years 3. Patients to be subjected to Single-shot spinal anaesthesia (SSS) or combined spinal-epidural (CSE) anaesthesia 4. ASA Classification ?-?

Exclusion criteria

Exclusion criteria: 1. Patients with mental, neurological diseases, or cognitive dysfunction 2. Patients taking sedation, analgesia and psychotropic drugs for a long time 3. Patients with metabolic and autoimmune diseases 4. Chronic alcohol or drug users 5. Neuromuscular diseases (specifically, truncation, myasthenia gravis) 6. Patients with spinal trauma or severe lumbar pain, severe systemic infection or lumbar infection 7. Combined with heart disease (pacemaker placement, frequent arrhythmia, atrial fibrillation, etc.) and lung disease (lung infection, emphysema, chronic complicating lung disease, etc.) 8. Impairment of liver and kidney function (ALT and/or AST >1.5 times the normal range, BUN and/or Cr>Upper limit of normal) 9. Patients with preoperative coagulopathy (PT/APTT above the upper limit of the reference value), recent or long-term use of anticoagulant or antiplatelet agents 10. Patients who did not sign the informed consent form or who refused to participate in the clinical trial after signing the informed consent form

Design outcomes

Primary

MeasureTime frame
metabonomics;proteomics;

Countries

China

Contacts

Public ContactZongze Zhang

Zhongnan Hospital of Wuhan University

zhangzz_0301@126.com13971687403

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026